COYA vs SO · rev $3.6M vs P/E 22, rev $29.55B
Coya Therapeutics, Inc. Common Stock (COYA) versus Southern Company (SO) — a side-by-side from cached financials, not a winner call.
Coya Therapeutics, Inc. Common Stock (COYA) is a biotechnology company listed on NASDAQ.
Southern Company (SO) is a utilities - regulated electric company listed on US.
Latest reported COYA revenue for 2024-12-31 was $3.6M. Net income was -$14.9M. Revenue was down 40.8% from 2023-12-31 to 2024-12-31. COYA currently screens at market cap $118.0M.
Latest reported SO revenue for 2025-12-31 was $29.55B. Net income was $4.34B. Revenue was up 10.6% from 2024-12-31 to 2025-12-31. SO currently screens at market cap $101.55B and trailing P/E 22.1.
COYA currently screens at market cap $118.0M. SO currently screens at market cap $101.55B and trailing P/E 22.1.
Not investment advice. Open the COYA and SO stock pages for the full models.
Not investment advice.